Developing innovative drugs for the treatment of Crohn's Disease, COVID-19, Progressive Multiple Sclerosis (pro-MS) and Hepatocellular Carcinoma (HCC)

Learn more about Tiziana

Tiziana Life Sciences Announces Death of Director

13 January 2022

Tiziana Life Sciences today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a member of Tiziana Life Science’s Board of Directors since February 2021.

Read more

Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

10 January 2022

  • - Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response

  • - FDA allows...

Read more

Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference

06 January 2022

NEW YORK, January 6, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference and be available for...

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of treating Crohn's Disease, COVID-19, Pro-MS and HCC and optimizing health outcomes.

Learn more

Clinical Candidates

With two Phase II and two pre-clinical candidates our development portfolio is supported by extensive IP and a strong pipeline of in-licensed clinical and pre-clinical assets.

Clinical development pipeline

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and a neurodegenerative indication.

Learn more about Foralumab

Milciclib

Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.

Learn more about Milciclib

Pre-Clinical Candidates

With several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipeline of in-licenced clinical and pre-clinical assets.

Anti IL-6R mAb (TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for certain patients infected with COVID-19.

Learn more about Anti IL-6R

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab and Milciclib

Foralumab

Tiziana reported postive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 2 for both orally administered Foralumab for the treatment of Crohn's disease and nasally administered Foralumab for the treatment of Pro-MS is anticipated to be complete in Q2 2021.

See more Foralumab clinical trials

Milciclib

We reported positive Phase 2a clinical data exhibiting positive clinical activity with Milciclib Monotherapy in advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma. We intend to initiate Phase 2b with Milciclib in Combination with a TKI in Q2 2021

See more Milciclib clinical trials

Tiziana Life Sciences is listed on NASDAQ